Dr Kathy Fuller (Heel) earned her PhD from The University of Western Australia for research into the effects of post-surgical nutrition on gut immunity. She was awarded a Raine Medical Research Foundation grant to continue her research, received a Queen's Trust for Young Australians Award to travel to Oxford University and study advanced immunohistochemistry techniques and won the WA Young Australian of the Year Award (Science and Technology). Dr Fuller continued developing models of human disease as a postdoctoral researcher at Thrombogenix at Monash University designing and optimising in vivo models of thombogenesis, including real-time imaging of thrombus formation in rodent mesentery using fluorescence microscopy. Dr Fuller returned to UWA, becoming the lead academic of the flow cytometry and cell sorting facility located in the Centre for Microscopy Characterisation and Analysis where she gained extensive experience in flow cytometry including development and validation of the Sperm Chromatin Structure Assay (SCSA) for routine diagnostic use by Western Australian embryology clinics. In 2012 Dr Fuller joined Prof Wendy Erber as Scientific Lead in the Translational Cancer Pathology Laboratory where she is developing imaging cytometry protocols for the analysis of haematological malignancies and minimal residual disease. Dr Fuller is co-inventor of “immuno-flowFISH”, a world-first automated flow cytometry method that can detect chromosome signals inside cells identified by their immunophenotype. Her development of this patented method was awarded the Australian Museum ANSTO 2018 Eureka Prize for Innovative Use of Technology. She lectures on standard flow and imaging flow cytometry techniques for research and diagnosis to third year biomedical science undergraduates and Masters postgraduate students. 

• Associate Professor of Translational Oncology, School of Biomedical Sciences
• Scientific lead in the Translational Cancer Pathology Laboratory (TCPL)

• Future Health Research Innovation (FHRI)
• NHMRC Ideas
• Channel 7 Telethon
• Foundation for Australia Japan Studies
• SH Oman Bequest for Cancer Research
• Perpetual Philanthropic Services, Ann Helen Toakley Charitable Endowment
• UWA Faculty of Health and Medical Sciences Research Grant
• Cancer Council of Western Australia
• NHMRC Equipment Grants
• ARC Linkage Infrastructure Equipment Facilities
• UWA Research Collaboration Awards
• UWA Faculty of Medicine, Dentistry and Health Sciences Infrastructure Grant
• Neurotrauma Research Program (NRP)
• Lotteries Commission Medical Research Program
• Royal Perth Hospital Medical Research Foundation
• Raine Medical Foundation
• Clive and Vera Ramaciotti Foundations: Equipment Grant-in-Aid

Pathwest Scientist in Charge and UWA Adjunct Senior Research Fellow, Pathwest/UWA Translational Cancer Pathology Laboratory, UWA (2016-2019)
Senior Research Fellow, Pathwest/UWA Translational Cancer Pathology Laboratory, UWA (2012-2016)
Academic in Charge of Flow Cytometry and Lecturer, Centre for Microscopy, Characterisation and Analysis (CMCA) (2006-2012)
Deputy Director and Associate Lecturer, Biomedical Imaging and Analysis Facility (BIAF), UWA (2004-2006)
Manager/Operator, Lotteries Flow Cytometry Unit (LFCU), UWA (2002-2003)
Senior Research Officer, Lotteries Laser Microdissection Facility (LLMF), UWA (2000-2003)
Senior Research Scientist, Thrombogenix Pty. Ltd., Department of Medicine, Monash University (1998-2000)
Principal Scientific Investigator, Department of Surgery (Royal Perth Hospital), UWA (1996-1998)

Dr Fuller is Co-Unit Coordinator for Cancer Pathology (PATH3309) and lectures on flow cytometry techniques for research and diagnosis of haematological malignancies to UWA students in Molecular Medicine (PATH2211), Body Defences (IMED2001), Infection and Immunity (MICR5842), and Haematology (PATH5161). 

Development of imaging cytometry protocols for diagnosis and prognosis in haematological malignancies.
Investigating megakaryocyte dysregulation and myelofibrotic progression in Myeloproliferative Neoplasms (MPN).
Investigating biomarkers of metastatic risk in colorectal carcinoma.